The Indo-UK FTA is expected to strengthen supply chains for pharma and medical devices sectors, improve access to inexpensive drugs and pave the way for cooperation in wholesale medicines and joint research. The domestic pharma industry is an optimistic export of generic drugs in the UK – currently a price of about 1 billion dollars – a boost will appear.Sudarshan Jain, general secretary of the Indian Pharmaceutical Alliance, said that the Pact provides opportunities to supply cheap and quality-wonderful drugs, contributing to better patient care in the UK. Namit Joshi, president of Pharmaccil, paved the agreement for the partnership in bulk drug imports, CDMOs and joint research, which strengthens India’s competitive edge.The medical devices industry also expects to accelerate bilateral trade. “Earlier, the equipment imported in the UK was duty-free, so tariffs were not a concern. But the regulator approval was costs and deadlines. We sought the UK CDSCO or QCI certificates for rapid track approval,” Rajeev Nath, Forum Coordinator, said. He highlighted the need for strict rules of original check to prevent misuse of FTA.
